Trending...
- Sober.Buzz the Sober Token : Ticker $BUZZ
- Art Imagined Photography to Be Showcased at Expo Metro Barcelona's The Art Tunnel
- Global Families Turn to Young Travelers Concierge Amid Rising Safety Concerns in the U.S
BELLEFONTE, Pa. - PennZone -- Actuated Medical, a pioneering company dedicated to developing innovative medical device solutions, is thrilled to announce the successful launch of the $1.5M First Tranche of their $10M Series A with Participating Preferred Shares. This significant financing milestone comes after successful due diligence and the execution of a term sheet with lead investor Keiretsu Forum Mid-Atlantic, South-East, & Texas (MST).
This funding will allow Actuated Medical to execute on commercialization milestones generated through discussions with Strategic Partners with interest in Actuated Medical technologies. The financing goal is to commercialize two FDA cleared medical devices and, in parallel, grow their clinical neural device portfolio.
Neural implants have the potential to treat neural diseases like Parkinson's and Epilepsy by using small electrical fields to mitigate the disruptive signals causing symptoms. Actuated Medical's neural device team is working to solve two major challenges with neural implants – how to insert them precisely and gently to target, and how to keep the body from walling them off with scar tissue. The goal is to revolutionize the approach to neural device design, placement, and treatment approaches.
"We are excited to partner with Keiretsu Forum-MST, whose expertise and network will be invaluable as we move forward," said Maureen L. Mulvihill, CEO of Actuated Medical. "This investment tranche marks a pivotal moment in our journey, allowing us to bring our innovative solutions to market more quickly and effectively."
More on The PennZone
Keiretsu Forum-MST is recognized for its commitment to supporting innovative companies through strategic investments and resources. Their involvement will not only provide financial backing but also strategic guidance as Actuated Medical seeks to enhance its product offerings and expand its reach in the healthcare sector.
"Actuated Medical exemplifies the kind of company we look for at Keiretsu Forum—innovative, capital-efficient, and led by a proven entrepreneur," said Howard Lubert, Regional President Keiretsu Forum-MST. "Dr. Maureen L. Mulvihill's ability to advance multiple technologies using over $48 million in non-dilutive funding is nothing short of extraordinary. This Series A round is a strategic step toward commercializing breakthrough solutions that can significantly improve patient care."
Actuated Medical remains committed to its mission of improving patient outcomes and accessibility to advanced medical technologies. The support from the Keiretsu Forum demonstrates confidence in their vision, and the possibilities ahead.
About Actuated Medical, Inc.
Actuated Medical is a medical technology innovator that is pioneering motion-based solutions to address critical, unmet clinical needs in gastroenterology and neurology. With an unwavering focus on innovation, safety, and superior quality, the Actuated team is committed to delivering transformative products that empower healthcare professionals to achieve greater precision, enhance efficiency, and drive better patient outcomes while reducing healthcare costs. The company's technologies are backed by a strategic path to commercialization with multiple exit opportunities, supported by invaluable feedback from industry leaders. Actuated holds 43 issued U.S. and international patents, 8 FDA 510(k) clearances, 5 Investigational Device Exemptions (IDEs), 33 pre-submissions, and has completed or is conducting 8 clinical studies. Actuated has been honored with two Small Business Administration (SBA) Tibbetts Awards for SBIR commercialization excellence (2014 & 2020). Actuated operates out of a state-of-the-art 20,000 sq. ft. facility in central Pennsylvania, and is certified ISO 13485, reflecting its steadfast commitment to quality and innovation. actuatedmedical.com
More on The PennZone
About Keiretsu Forum:
Keiretsu Forum is the world's largest private equity angel investment network, with over 2,000 accredited investors across 34 North American and 23 international chapters. The forum has invested over $1 billion in early-stage companies in the past 23 years, covering diverse sectors such as technology, life sciences, fintech, and sustainable technologies.
###
For media inquiries, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.
Additional information can be found by visiting:
ActuatedMedical.com
ActuatedNeuroscience.com
TubeClear.com
GripTract.com
This funding will allow Actuated Medical to execute on commercialization milestones generated through discussions with Strategic Partners with interest in Actuated Medical technologies. The financing goal is to commercialize two FDA cleared medical devices and, in parallel, grow their clinical neural device portfolio.
Neural implants have the potential to treat neural diseases like Parkinson's and Epilepsy by using small electrical fields to mitigate the disruptive signals causing symptoms. Actuated Medical's neural device team is working to solve two major challenges with neural implants – how to insert them precisely and gently to target, and how to keep the body from walling them off with scar tissue. The goal is to revolutionize the approach to neural device design, placement, and treatment approaches.
"We are excited to partner with Keiretsu Forum-MST, whose expertise and network will be invaluable as we move forward," said Maureen L. Mulvihill, CEO of Actuated Medical. "This investment tranche marks a pivotal moment in our journey, allowing us to bring our innovative solutions to market more quickly and effectively."
More on The PennZone
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
Keiretsu Forum-MST is recognized for its commitment to supporting innovative companies through strategic investments and resources. Their involvement will not only provide financial backing but also strategic guidance as Actuated Medical seeks to enhance its product offerings and expand its reach in the healthcare sector.
"Actuated Medical exemplifies the kind of company we look for at Keiretsu Forum—innovative, capital-efficient, and led by a proven entrepreneur," said Howard Lubert, Regional President Keiretsu Forum-MST. "Dr. Maureen L. Mulvihill's ability to advance multiple technologies using over $48 million in non-dilutive funding is nothing short of extraordinary. This Series A round is a strategic step toward commercializing breakthrough solutions that can significantly improve patient care."
Actuated Medical remains committed to its mission of improving patient outcomes and accessibility to advanced medical technologies. The support from the Keiretsu Forum demonstrates confidence in their vision, and the possibilities ahead.
About Actuated Medical, Inc.
Actuated Medical is a medical technology innovator that is pioneering motion-based solutions to address critical, unmet clinical needs in gastroenterology and neurology. With an unwavering focus on innovation, safety, and superior quality, the Actuated team is committed to delivering transformative products that empower healthcare professionals to achieve greater precision, enhance efficiency, and drive better patient outcomes while reducing healthcare costs. The company's technologies are backed by a strategic path to commercialization with multiple exit opportunities, supported by invaluable feedback from industry leaders. Actuated holds 43 issued U.S. and international patents, 8 FDA 510(k) clearances, 5 Investigational Device Exemptions (IDEs), 33 pre-submissions, and has completed or is conducting 8 clinical studies. Actuated has been honored with two Small Business Administration (SBA) Tibbetts Awards for SBIR commercialization excellence (2014 & 2020). Actuated operates out of a state-of-the-art 20,000 sq. ft. facility in central Pennsylvania, and is certified ISO 13485, reflecting its steadfast commitment to quality and innovation. actuatedmedical.com
More on The PennZone
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
About Keiretsu Forum:
Keiretsu Forum is the world's largest private equity angel investment network, with over 2,000 accredited investors across 34 North American and 23 international chapters. The forum has invested over $1 billion in early-stage companies in the past 23 years, covering diverse sectors such as technology, life sciences, fintech, and sustainable technologies.
###
For media inquiries, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.
Additional information can be found by visiting:
ActuatedMedical.com
ActuatedNeuroscience.com
TubeClear.com
GripTract.com
Source: Actuated Medical, Inc.
0 Comments
Latest on The PennZone
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Children's Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation
- GormanSquared Announces Provisional Patent
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- Chewy Chums™ Launches NeverBite™ on Kickstarter
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
- Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
- Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
- New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions